Steven R A Simoens (Steven Simoens)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 34

Top Topics

Positive Breast Cancer

Respiratory Syncytial Virus

Epidermal Growth Factor Receptor

Rheumatoid Arthritis Patients

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Pharmaceuticals (Basel, Switzerland)

Journal of market access & health policy

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Khadidja Abdallah, Isabelle Huys, Kathleen J Claes, Steven R A Simoens
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease. Clinical drug investigation (2024)
Khadidja Abdallah, Isabelle Huys, Kathleen J Claes, Steven R A Simoens
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease. Clinical drug investigation 44 (8) (2024)
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven R A Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G M Mol, Anja Schiel, Wim G Goettsch, Hendrika van den Ham, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. Journal of market access & health policy 12 (1) (2024)
Khadidja Abdallah, Isabelle Huys, Kathleen J Claes, Steven R A Simoens
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease. Clinical drug investigation 44 (8) (2024)
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven R A Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G M Mol, Anja Schiel, Wim G Goettsch, Hendrika van den Ham, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. Journal of market access & health policy 12 (1) (2024)
Amber Werbrouck, Masja Schmidt, Koen Putman, Steven R A Simoens, Nick Verhaeghe, Lieven Annemans
Cost-Utility of an Exercise Referral Scheme Versus Doing Nothing in Flemish Adults: Exploring the Impact of Key Assumptions. Journal of physical activity & health (2023)
Maarten J Postma, Chih-Yuan Cheng, Nasuh C Buyukkaramikli, Luis Hernandez Pastor, Ine Vandersmissen, Thierry Van Effelterre, Peter J M Openshaw, Steven R A Simoens
Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 11 (5) (2023)
Maarten J Postma, Chih-Yuan Cheng, Nasuh C Buyukkaramikli, Luis Hernandez Pastor, Ine Vandersmissen, Thierry Van Effelterre, Peter J M Openshaw, Steven R A Simoens
Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium". Vaccines 11 (11) (2023)
Yannick Vandenplas, Steven R A Simoens, Florian Turk, Arnold G Vulto, Isabelle Huys
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines. Applied health economics and health policy 20 (6) (2022)
Teresa Barcina Lacosta, Arnold G Vulto, Adina Turcu-Stiolica, Isabelle Huys, Steven R A Simoens
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 36 (2) (2022)
Steven R A Simoens, Isabelle Huys
Emerging Insights into European Markets of Biologics, Including Biosimilars. Pharmaceuticals (Basel, Switzerland) 15 (5) (2022)
Liese Barbier, Steven R A Simoens, Arnold G Vulto, Isabelle Huys
European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (6) (2021)
Liese Barbier, Steven R A Simoens, Caroline Soontjens, Barbara Claus, Arnold G Vulto, Isabelle Huys
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Binita Dutta, Isabelle Huys, Arnold G Vulto, Steven R A Simoens
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (2) (2021)
Brian B Godman, Andrew Hill, Steven R A Simoens, Gisbert W Selke, Iva Selke Krulichová, Carolina Zampirolli Dias, Antony Paul Martin, Wija Oortwijn, Angela Timoney, Lars L Gustafsson, Luka Voncina, Hye-Young Kwon, Jolanta Gulbinovic, Dzintars Gotham, Janet Wale, Wânia Cristina da Silva, Tomasz Bochenek, Eleonora Allocati, Amanj Baker Kurdi, Olanyika O Ogunleye, Johanna Catharina Meyer, Iris Hoxha, Admir Malaj, Christian Hierländer, Robert Sauermann, Wouter Hamelinck, Guenka Petrova, Ott Laius, Irene Langner, John N Yfantopoulos, Roberta Joppi, Arianit Jakupi, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Jf Hans Piepenbrink, Vincent de Valk, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Jurij Fürst, Dominik Tomek, Mercè Obach, Corinne Zara Yahni, Caridad Pontes, Stuart McTaggart, Tracey-Lea Laba, Øyvind Melien, Durhane Wong-Rieger, Seung Jin Bae, Ruaraidh A Hill
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert review of pharmacoeconomics & outcomes research 21 (4) (2021)
Masja Schmidt, Amber Werbrouck, Nick Verhaeghe, Koen Putman, Steven R A Simoens, Lieven Annemans
Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations. Applied health economics and health policy 18 (2) (2021)
Amber Werbrouck, Masja Schmidt, Lieven Annemans, Joke Duyck, Barbara E Janssens, Steven R A Simoens, Nick Verhaeghe, Koen Putman
Oral healthcare delivery in institutionalised older people: A health-economic evaluation. Gerodontology (2021)
Liese Barbier, Steven R A Simoens, Arnold G Vulto, Isabelle Huys
European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (6) (2021)
Evelien Moorkens, Arnold G Vulto, James Kent, Lindsay McClure, Richard Boldero, Thibault Vanhove, Steven R A Simoens, Isabelle Huys
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (1) (2021)
Yannick Vandenplas, Steven R A Simoens, Philippe Van Wilder, Arnold G Vulto, Isabelle Huys
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals (Basel, Switzerland) 14 (2) (2021)
Steven R A Simoens, Arnold G Vulto, Pieter Dylst
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. Pharmaceuticals (Basel, Switzerland) 14 (5) (2021)
Liese Barbier, Yannick Vandenplas, Steven R A Simoens, Paul J Declerck, Arnold G Vulto, Isabelle Huys
Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. Journal of pharmaceutical policy and practice 14 (1) (2021)
Carolina Zampirolli Dias, Brian B Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Maurílio de Souza Cazarim, Laís Lessa Neiva Pantuzza, Nelio Gomes Ribeiro-Junior, André Luiz Pereira, Marcus Carvalho Borin, Isabella de Figueiredo Zuppo, Roberto Iunes, Tomas Pippo, Renata Curi Hauegen, Carlos Vassalo, Tracey-Lea Laba, Steven R A Simoens, Sergio Márquez, Carolina Gomez, Luka Voncina, Gisbert W Selke, Livio Garattini, Hye-Young Kwon, Jolanta Gulbinovic, Aneta Lipinska, Maciej Pomorski, Lindsay McClure, Jurij Fürst, Rosana Gambogi, Carla Hernandez Ortiz, Vânia Cristina Canuto Santos, Denizar Vianna Araújo, Vânia Eloisa de Araújo, Francisco de Assis Acurcio, Juliana Álvares Teodoro, Augusto Afonso Guerra Junior
Integrative Review of Managed Entry Agreements: Chances and Limitations. PharmacoEconomics 38 (11) (2021)
HoUng Kim, Rieke E Alten, J R Fraser Cummings, Silvio Danese, Geert R A M D'Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, Jong Hyuk Lee, James O Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven R A Simoens, René Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13 (1) (2021)
Kim Pauwels, Isabelle Huys, Minne Casteels, Yvonne Denier, Martina Vandebroek, Steven R A Simoens
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population. Applied health economics and health policy 17 (6) (2020)
Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G Vulto, Steven R A Simoens
Economic evaluation of biosimilars for reimbursement purposes - what, when, how? Journal of market access & health policy 8 (1) (2020)
HoUng Kim, Rieke E Alten, Luisa Avedano, Axel U Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M Irving, Prof Jørgen Jahnsen, Péter L Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven R A Simoens, René Westhovens, Silvio Danese, Ji Hoon Jeong
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80 (2) (2020)
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert W Selke, Isabelle Huys, Steven R A Simoens
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals (Basel, Switzerland) 13 (10) (2020)
Ilda Hoxhaj, Laurenz Govaerts, Steven R A Simoens, Walter Van Dyck, Isabelle Huys, Iñaki Gutierrez-Ibarluzea, Stefania Boccia
A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies. International journal of environmental research and public health 17 (21) (2020)
Arnold G Vulto, Jackie Vanderpuye-Orgle, Martin van der Graaff, Steven R A Simoens, Lorenzo Dagna, Richard Macaulay, Beenish Majeed, Jeffrey Lemay, Jane Hippenmeyer, Sebastian Gonzalez-McQuire
Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review. Pharmaceuticals (Basel, Switzerland) 13 (11) (2020)
Minyoung Jang, Steven R A Simoens, Taeksang Kwon
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (1) (2020)
Steven R A Simoens, Raymond Cheung
Tendering and biosimilars: what role for value-added services? Journal of market access & health policy 8 (1) (2019)
Liese Barbier, Paul Declerck, Steven R A Simoens, Patrick Neven, Arnold G Vulto, Isabelle Huys
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. British journal of cancer 121 (3) (2019)
Marc Dooms, David Cassiman, Steven R A Simoens
Off-label use of orphan medicinal products: a Belgian qualitative study. Orphanet journal of rare diseases 11 (1) (2016)